Formulation development of Derris scandens gel for muscle pain in athletes

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180608003

Enrollment

Unknown

Registered

2018-06-08

Start date

2018-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers Derris scandens&#44

Interventions

Derris scandens gel ,diclofenac gel

Active Comparator Drug,Active Comparator Drug

Derris scandens gel,diclofenac gel

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Athlete with eccentric exercise of legs, without the competition for 6 months, live in Maha Sarakham Province, no enroll in other clinical study

Exclusion criteria

Exclusion criteria: be injured for 2 months, muscle pain from the exercise before 6 weeks, using the opioids within 7 days, using the corticosteroids both of oral and topical within 60 days, using the non-steroidal anti-inflamatory drugs after injury, using the analgesic drugs after injury, allergy in non-steroidal anti-inflamatory drugs allergy in Derris scandens

Design outcomes

Primary

Measure	Time frame
Pain level Day 0, 1, 3, 7 Pain score	—

Secondary

Measure	Time frame
Muscle strength Day 0, 1, 3, 7 Counter movement jump	—

Countries

Thailand

Contacts

Public ContactCatheleeya Mekjaruskul

Faculty of Pharmacy, Mahasarakham University

catheleeya.m@msu.ac.th66817685684

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026